Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase.

Autor: Alswied A; Department of Pathology, University of Arizona, Tucson, AZ USA. Electronic address: alswied@pathology.arizona.edu., Rehman A; Department of Pathology, University of Arizona, Tucson, AZ USA., Lai LW; Department of Pathology, University of Arizona, Tucson, AZ USA., Duran J; Department of Pathology, University of Arizona, Tucson, AZ USA., Sardar M; Division of Hematology and Medical Oncology, Department of Medicine, University of Arizona, Tucson, AZ USA., Proytcheva MA; Department of Pathology, University of Arizona, Tucson, AZ USA.
Jazyk: angličtina
Zdroj: Cancer genetics [Cancer Genet] 2021 Apr; Vol. 252-253, pp. 111-114. Date of Electronic Publication: 2021 Jan 19.
DOI: 10.1016/j.cancergen.2021.01.006
Abstrakt: Clonal cytogenic evolution with the development of additional chromosomal abnormalities (ACAs) in chronic myelogenous leukemia (CML) is a marker for disease progression and is known to impact therapy and survival. The presence of ACAs has been shown to affect the responses to tyrosine kinase inhibitors (TKI) in patients with newly diagnosed CML in accelerated phase (CML-AP). We report a rare case of a CML patient who presented in CML-AP and was found to have multiple ACAs including monosomy 7, deletion 7p, trisomy 8, and an extra Philadelphia chromosome (Ph) in separate Ph-positive cell line, respectively. Six months after combined chemotherapy with TKI, the patient achieved a major cytogenetic response with disappearance of monosomy 7/deletion 7p with no major molecular response.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: